3 results
We need objective and validated tests for the assessment of the severity of impairment in CFS/ME patients. In 2 areas these tests will be essential: for studies of the effect of interventions and for the assessment of disability.Hardly any research…
* To assess the safety and tolerability of Ampligen administered intranasally in a dosing schedule for 13 days (7 doses) in healthy subjects.* To characterize the mucosal immune response following Ampligen administration over time.
The primary objective of the safety run-in (phase Ib) is to determine the safety of combination therapy with durvalumab and rintatolimod. The primary objective of the phase II trial is to determine the clinical benefit rate of combination therapy…